Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00316719 | Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients | PHASE3 | COMPLETED | 105 | — | — | Jan 1, 2006 | Jan 1, 2008 | Oct 6, 2009 | - | — |
Change from baseline was the difference of the HBV DNA copy numbers (log10) in serum collected by blood draw between baseline and Week 52
| Arm | Type | Description |
|---|---|---|
| Adefovir Dipivoxil (ADV) | EXPERIMENTAL | - |
| Lamivudine (LAM) | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| LAM group | DRUG | Subjects took one LAM 100mg tablet orally once daily and one ADV placebo tablet orally once daily. |
| ADV group | DRUG | Subjects took one ADV 10mg tablet orally once daily and one LAM placebo tablet orally once daily. |
Inclusion criteria: * Have compensated chronic hepatitis B. * Have not been treated with anti HBV agents with antiproliferative activity against. However, previous Interferon (IFN) therapy is permitted. * Ability to read, understand, and sign the informed consent. * Have a positive serum HBV-DNA \>...